Aurobindo Pharma is currently trading at Rs. 603.80, up by 7.70 points or 1.29% from its previous closing of Rs. 596.10 on the BSE.
The scrip opened at Rs. 595.50 and has touched a high and low of Rs. 604.60 and Rs. 593.60 respectively. So far 59322 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 566.00 on 19-Jul-2018.
Last one week high and low of the scrip stood at Rs. 625.65 and Rs. 588.00 respectively. The current market cap of the company is Rs. 35398.09 crore.
The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 35.16% and 12.97% respectively.
The US Food and Drug Administration (USFDA) has pulled up Aurobindo Pharma for 'repeated' violations in current good manufacturing practice (CGMP) at three of its plants in manufacturing certain active pharmaceutical ingredients (API) and intermediates. The repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs are inadequate.
The FDA recently issued a letter warning the drug- makers unit X1 in Srikakulam district of Andhra Pradesh for deviations from CGMP for API. Aurobindo unit I and Aurobindo unit IX were also inspected and cited for CGMP deficiencies related to the manufacture of (b)(4) API and intermediates. These facilities were also considered to be in an unacceptable state of compliance with regards to CGMP.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.